LHPP suppresses proliferation, migration, and invasion and promotes apoptosis in pancreatic cancer.

Biosci Rep

Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China.

Published: March 2020

Pancreatic cancer (PaCa) is a common malignant tumor of the digestive system with poor prognosis and no ideal treatment for inoperable patients, which is partly due to delayed diagnoses. It is recently reported that the protein histidine phosphatase LHPP is a tumor suppressor in hepatocellular carcinoma, cervical cancer, and bladder cancer. So far, there is no study on the expression level of LHPP in PaCa, and its mechanism of action on tumors is unclear. In this experiment, LHPP expression was lower in cancer tissues than that in normal pancreatic tissue, and clinicopathological results showed that LHPP expression was correlated with the degree of differentiation and lymphatic metastasis of pancreatic carcinoma. The biological characteristics of LHPP in PaCa cells were examined by the cell counting kit-8 assay, transwell assay, and monoclonal formation test. The inhibitory mechanism of LHPP in PaCa cells was determined using Western blotting and flow cytometry. The results showed that LHPP restrained PaCa cell proliferation, migration, and invasion. Increased LHPP expression promoted the apoptosis of PaCa cells through higher activation of cleaved-PARP and cleaved-Casp3 and lower activation of cIAP1. Importantly, the increase in LHPP enhanced PTEN expression and decreased the phosphorylated AKT level. Moreover, LHPP-induced apoptosis was diminished by SC79 (AKT activator) in PaCa cells. In conclusion, LHPP blocks proliferation, migration, and invasion and enhances apoptosis in PaCa cells through the PTEN/AKT signaling pathway.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103587PMC
http://dx.doi.org/10.1042/BSR20194142DOI Listing

Publication Analysis

Top Keywords

paca cells
20
proliferation migration
12
migration invasion
12
lhpp paca
12
lhpp expression
12
lhpp
11
pancreatic cancer
8
paca
8
apoptosis paca
8
cancer
5

Similar Publications

The Chansu injection (CSI), a sterile aqueous solution derived from Chansu, is applied in clinical settings to support antitumor and anti-radiation treatments. CSI's principal active components, bufadienolides (≥90%), demonstrate potential effects on pancreatic cancer (PDAC), but their underlying mechanisms remain unclear. This study aimed to elucidate the antitumor effects and pathways associated with CSI in PDAC.

View Article and Find Full Text PDF

Phytochemical Study and In Vitro Antioxidant Activity of Along with Antitumor Activity of the Isolated -Tiliroside and Luteolin 4'--β-Xyloside.

Molecules

December 2024

Laboratory of Chemistry and Environmental Chemistry (LCCE), Department of Chemistry, Faculty of Matter Sciences, University of Batna 1, Batna 05000, Algeria.

Twelve compounds (-), kaempferol (), luteolin (), luteolin 4'--xyloside (), luteolin 4'--β-glucoside (), quercetin 4'--β-xyloside (), kaempferol-3--[6″--(E)-p-coumaroyl]-β-D-glucoside (-tiliroside) (), protocatechuic acid (), gallic acid (), methyl gallate (), ethyl gallate (), shikimic acid-3--gallate (), and 3,3',4'-tri--methyl-ellagic acid 4-sulfate (), were isolated and identified from the aerial parts of (Cav.) Pers (synonym: C. Presl.

View Article and Find Full Text PDF

Different Cytotoxic Effects of Cisplatin on Pancreatic Ductal Adenocarcinoma Cell Lines.

Int J Mol Sci

December 2024

Dipartimento di Scienze e Tecnologie Biologiche e Ambientali (Di.S.Te.B.A.), Università del Salento, Via Provinciale per Monteroni, 73100 Lecce, Italy.

This study examined the response to cisplatin in BxPC-3, Mia-Paca-2, PANC-1, and YAPC pancreatic cancer lines with different genotypic and phenotypic characteristics, and the mechanisms associated with their resistance. BxPC-3 and MIA-PaCa-2 cell lines were the most sensitive to cisplatin, while YAPC and PANC-1 were more resistant. Consistently, in cisplatin-treated BxPC-3 cells, the cleavage patterns of pro-caspase-9, -7, -3, and PARP-1 demonstrated that they were more sensitive than YAPC cells.

View Article and Find Full Text PDF

10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer.

Front Oncol

December 2024

Research Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.

Various therapeutic strategies have been developed to treat Pancreatic Cancer (PaCa). Unfortunately, most efforts have proved unfruitful, as the poor prognosis observed in this disease has only attained little improvement in the past 40 years. Recently, deeper understanding of the immune system and its interaction with malignant tumors have allowed significant advances in immunotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Pancreatic ductal adenocarcinomas (PDAC) are highly aggressive and lack effective treatments; this study examines potential new therapies using rat monoclonal antibodies (mAbs) targeting specific membrane proteins.
  • Key membrane proteins such as HER1-4, MET, S1PR1, LAT1, and CD44v are frequently expressed in PDAC, and targeting them with mAbs demonstrated growth inhibition in various cancer cell lines.
  • High levels of CD44v in PDAC correlate with poor patient prognosis, indicating that targeting CD44v and related proteins could provide new diagnostic and therapeutic avenues for treating this aggressive cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!